Back

                  ASTRAZENECA PHARMA INDIA LIMITED

Regd. Office : Off Bellary Road, Hebbal, Bangalore 560 024

AUDITED FINANCIAL  RESULTS FOR THE

QUARTER  AND HALF YEAR ENDED 30th JUNE 2003

Rs. in lakhs
Sl Particulars 3 months Corresponding Year to date Year to date Previous
ended 3 months in figures for figures for Accounting
current the previous current previous year
year  year year  year  ended
30.06.2003 30.06.2002 30.06.2003 30.06.2002 31.12.2002
(Audited) (Unaudited) (Audited) (Audited) (Audited)
1 Net Sales/Income from operations 4927.87 3280.02 8149.77 5880.95 13617.19
2 Service Income         38.48 68.57 72.51

         68.57

144.55
3 Other Income         89.34 59.17 219.89 156.13 307.38
4 Total Expenditure
   (a) Increase(-)/decrease(+) in stock-in-trade       569.48 255.09 808.41 -53.52 -1721.54
   (b) Consumption of raw and packing materials       919.78 706.60 1729.35 1705.59 4376.14
   (c) Purchase of finished goods       396.89 527.81 671.70 818.47 2760.45
   (d) Staff cost       710.20 630.43 1357.31 1190.69 3004.60
   (e) Rates & taxes               -   0.00 0.00 0.00
   (f) Excise duty               -   0.00 0.00 0.00
   (e) Other expenditure       905.50 763.48 1666.38 1680.45 3478.34
5 Interest           1.91 1.77                1.91 5.44 7.87
6 Depreciation       102.47 113.13 213.05 215.19 485.33
7 Profit (+) / Loss (-) before tax and prior period     expenditure (1+2+3-4-5-6) 1449.46 409.45 1994.06 543.34 1677.93
8 Prior period expenditure               -                      -                      -   33.21               -  
9 Profit(+)/Loss(-) before tax (7-8 ) 1449.46 409.45 1994.06 510.13 1677.93
10 Provision for taxation       554.44 170.00 764.44 240.00 905.72
11 Deferred Tax asset(+)/(liability)(-) for the period         23.80 21.57 -37.46 34.98 263.96
12 Net Profit(+) / Loss(-) for the period (9-10+11) 918.82 261.02 1192.16 305.11 1036.17
13 Paid-up Equity Share Capital 500.00 500.00 500.00 500.00 500.00
(Face value of Rs.10 per share)
14 Reserves excluding revaluation reserves               -                      -                      -                  -   7098.54
(as per Balance Sheet of previous
accounting year)
15 Basic and Diluted Earnings(+)/Loss(-) 18.38 5.22 23.84 6.10 20.72
(Rs) per share (not annualised)
16 Aggregate of non-promoter shareholding
 - Number of shares 419509
 - Percentage of shareholding 8.39%
Notes :
1.The  above  results  were  approved  by  the  Board of Directors of the Company at its meeting held on 26th August 2003.
2. The Company's sole business segment is HealthCare. The capital employed in this segment is Rs. 8,761.26 lakhs (12 months
    ended 31st December 2002 : Rs. 7,586.92 lakhs). The above results for 3 months and 6 months ended 30th June 2003 include
    non operational income (net of non operational expense) Rs. 1.66 lakhs (corresponding 3 months of previous year
2. Sales exclude excise duty and sales tax.
3. Inventory of finished goods includes excise duty.
5. The Company has for the first time accounted for deferred taxation for the year ended 31st March, 2001 and
    consequently figures for the quarter ended and six months ended 30th September, 2000 have not been adjusted
    for deferred taxation.
6. Hitherto, promotional items were valued as inventories.  In the current period, promotional items have been charged off to the profit and loss account.  As
    a result, inventories as at 31 March 2002 is lower by Rs. 20.66 lakhs and the profit before taxation for the period is lower by Rs. 20.66 lakhs.
4. Staff costs for the 12 months ended 31 December 2002 include Rs 505.74  (previous period: Rs Nil) incurred
   towards exgratia on account of early retirements. This liability has been accounted in accordance with the terms
   of the agreement entered into with each such employee during the year.
    Rs.11.06 lakhs) and Rs. 83.76 lakhs  (corresponding  6 months of previous year Rs. 47.06 lakhs) respectively (12 months  
    ended 31st December 2002: Rs. 46.93 lakhs).
3. There were no investor complaints pending as at the beginning of the quarter.The Company had received six investor
    complaints during the quarter ended 30th June, 2003.  All the complaints have been satisfactorily dealt with.
4. The Company has shifted its Registered Office on 18th August 2003 to the address mentioned above.
5. Previous period figures have been regrouped/ reclassified, wherever necessary.
                                                                                               By Order of the Board of Directors
                                                                                    For ASTRAZENECA PHARMA INDIA LIMITED
                                                                                                                 LARS WALAN
                                                                                                              Managing Director
Bangalore
Dated : 26th August 2003